Qiagen posts earnings; AtheroMed notches an FDA win; Covidien hunts for a new CFO;

@FierceMedDev:Zimmer finishes 2013 with a leg up from new products. Story | Follow @FierceMedDev

@MarkHFierce: Medtronic is shifting its Middle East HQ from Lebanon to Dubai. More growth opportunities and investment $ to tap. Story via The National | Follow @MarkHFierce

@GalenMoore: This may be the year Valeant writes the check that vaults it into the top tier of drugmakers. Story via Bloomberg | Follow @GalenMoore

@MichaelGFierce: Nanogold 'superstructures' are held together with DNA for cancer drug delivery. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: NeoGenomics launches 22 cancer profiling tests. Article | Follow @EmilyWFierce

> Qiagen ($QGEN) reports Q4 earnings: $106.3 million in adjusted operating income on $362.6 million net sales. Release

> The FDA has given AtheroMed the green light to market its Phoenix Atherectomy System. Report

> After his death, "H.M." divulges more about memory in new 3-D scans of a famous brain. Story

> The trial review board at Chicago's Mercy Hospital has received an FDA warning over human testing of medical devices. Report

> Medtronic ($MDT) is shifting its Middle East region HQ from Lebanon to Dubai. Item

> Covidien ($COV) is hunting for a new CFO. Report

Biotech News

@FierceBiotech: Wilex cuts 80% of its staff as it pulls the plug on a once-promising cancer therapy. More | Follow @FierceBiotech

@JohnCFierce: Aveo now can't even recruit patients for a trial? They might want to consider a new biz model--outside of biotech. Release | Follow @JohnCFierce

@DamianFierce: KaloBios calls it quits on its asthma drug after a Phase II flop. Story | Follow @DamianFierce

@EmilyMFierce: J&J enlists Yale to oversee clinical trials data sharing. News | Follow @EmilyMFierce

> Progenics tanks after two trial deaths cast doubt on its lead program. Article

> Despite a years-long dry run, Lilly keeps the faith in its pipeline. Read

Pharma News

@FiercePharma: Lilly surprises on revenue even as Cymbalta sinks. Story | Follow @FiercePharma

@TracyStaton: BMS counts on DTC to keep driving Eliquis growth. But are its ads much different from rivals? News | Follow @TracyStaton

@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce

@CarlyHFierce: Vertex profits on one-time gain despite plummeting Incivek sales. Item | Follow @CarlyHFierce

> Lilly surprises on revenue even as Cymbalta sinks. Story

> Roche highlights strong 2013 sales of cancer drugs, vows to boost dividend. Article

> Riding Big Pharma's open data wave, J&J taps Yale to manage requests. Item

Pharma Manufacturing News

> India's top drug regulator says he will do surprise inspections of foreign-owned plants. Story

> Novartis' production reduction plan has shed 20 plants in 4 years. Article

> Flu hospitalizations are putting pressure on saline manufacturers in face of shortage. Item

> Amgen confirms the $1B Ireland plant it postponed 7 years ago will not get built. Story

> Cytovance expands its biologics manufacturing and warehousing operations. News

> DOJ says to expect consent decrees like the one Ranbaxy signed as its tool of choice. Article

Vaccines News

> Survey: Anti-vaccine views have little correlation with politics. Story

> The NIH is infecting volunteers with flu to find out how the immune system works. News

> Production problem prompts GSK to stop worldwide deliveries of chickenpox vaccines. Article

> The U.K. is set to fall well short of flu vaccine uptake targets. Story

> Pfizer pins hopes on vaccine data to kick-start revenue growth. Story

> Novartis: We cannot keep shipping Bexsero under an investigational license. Item

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.